carismatx.com (CARM) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Carisma Therapeutics focuses on the global implementation of macrophage modification technologies to combat solid tumors, aiming to dominate the immunopharmaceuticals sector. High procedure margins are driven by a unique platform that enables the scaling of therapy worldwide. This chart illustrates the current share price of , confirming that the business is protected by patents and strict FDA oversight, which create an insurmountable barrier to entry.
carismatx.com - analytical breakdowns and key metrics (CARM)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Carisma Therapeutics|CARM - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Carisma Therapeutics Inc.|CARM - Company Cumulative Debt|Debts to Book Capitalization CARM|CARM - Company Long-Term Liabilities|Company Short-Term Debts Carisma Therapeutics|Quick Liquidity carismatx.com
- business earnings and investment ratios data:
CARM - Final Profit|Projected Future Earnings Carisma Therapeutics|CARM - Business Payback Period|Future Price to Earnings Carisma Therapeutics Inc.|CARM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CARM|CARM - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Carisma Therapeutics|CARM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months carismatx.com|CARM - Earnings per share increase in current year|Expected earnings per share growth for next year Carisma Therapeutics
- sales and revenue data:
Initial company analysis:Carisma Tx CARM
For Carisma Therapeutics (CARM), which is developing breakthrough CAR-macrophage technology to combat solid tumors, this indicator serves as a tool for assessing business value while accounting for debt load. The EV/EBITDA ratio dynamics for this capital-intensive business compare the total enterprise value with operating profit before interest and taxes, allowing investors to determine the extent of asset overvaluation relative to the actual ability to generate cash flow.
Competitors of Carisma Therapeutics (CARM)
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|Dianthus Corp (DNTH) - Enterprise Value to EBITDA Ratio|PHVS: EV/EBITDA Multiple|AbCellera (ABCL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio|PGEN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PHAR|Total Company Value to Operating Income Before Depreciation Ratio Nektar Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|Total Company Value to Operating Income Before Depreciation Ratio zenasbio.com (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Gossamer Bio Inc (GOSS) - Enterprise Value to EBITDA Ratio|KALV: EV/EBITDA Multiple|Septerna Pharma (SEPN) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PVLA|SVRA: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio RIGL (Rigel Pharmaceuticals, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ANAB|EV/EBITDA Multiple ATXS (Astria Pharma)|Business Value to Operating Income Before Depreciation ENGN|RAPT Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA Aerovate Therapeutics Inc|Aclaris Therapeutics, Inc. (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kyverna Therapeutics Inc. - Business Value to Operating Income Before Depreciation|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|EV/EBITDA Multiple Cabaletta Bio Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ventyx Biosciences (VTYX)|THTX: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AVTX (Avalo Therapeutics)|Eledon Pharmaceuticals Inc. (ELDN) - Company Value to EBITDA|AGEN: Enterprise Value to EBITDA Ratio|CLYM - EV/EBITDA Multiple|ZURA (Zura Bio) - Enterprise Value to EBITDA Ratio|ATYR: Enterprise Value to Operating Income Before Depreciation Ratio|ADAG (Adagene Inc) - EV/EBITDA Multiple|Ikena Oncology, Inc. (IMA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple STTK|Enterprise Value to EBITDA Ratio equilliumbio.com EQ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Connect Biopharma Holdings Limited CNTB|Total Company Value to Operating Income Before Depreciation Ratio Immunic Therapeutics (IMUX)|Atara Biotherapeutics Inc - EV/EBITDA Multiple|InflaRx N.V. (IFRX) - Enterprise Value to EBITDA Ratio|XFOR: EV/EBITDA Multiple|Adicet Bio, Inc. (ACET) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|INMB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Barinthus Biotherapeutics plc (BRNS)|Enterprise Value to EBITDA Ratio Kezar Life Sciences Inc. KZR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SAB Biotherapeutics, Inc SABS|AKTX (Akari Therapeutics, Plc) - Company Value to Operating Income Before Depreciation Ratio|Enlivex Therapeutics, Ltd. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation QTTB (Q32 Bio Inc.)|GOVX: EV/EBITDA Multiple|Edesa Biotech Inc (EDSA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iBio Corp|XTLB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics (BOLT)|Enterprise Value to EBITDA Ratio hcwbiologics.com HCWB|EV/EBITDA Multiple APVO (Aptevo Therapeutics Inc.)|EV/EBITDA Multiple aimimmuno.com AIM|ADTX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GRI (GRI Bio Corporation)|XRTX: EV/EBITDA Multiple|HIND - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|Enterprise Value to EBITDA Ratio calcimedica.com CALI|Affimed N.V. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Allakos Inc ALLK|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGMS (IGM Biosciences, Inc.) - Enterprise Value to Operating Income Before Depreciation|ITOS: EV/EBITDA Multiple|Company Value to EBITDA Ocean Biomedical Corp (OCEA)|TCBP (TC Biopharm) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio thirdharmonicbio.com (THRD)
